POLPHARMA-BIOLOGICS
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has concluded a commercial partnership with Teva Pharmaceutical Industries Ltd. for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®) in Europe, Canada, Israel and New Zealand.
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "wet" type of age-related macular degeneration, a common form of age-related vision loss. Worldwide, at least 25 to 30 million people are affected by age-related macular degeneration. The launch of a biosimilar Ranibizumab can increase market competition, reduce cost and expand patient access with proven analytical and clinical similarity to the original product.
This agreement with Teva complements an existing agreement concluded with Coherus BioSciences, Inc. for commercialisation in the United States.
Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented on the achievements of the joint venture:
“This is a huge milestone for the progression of a life changing therapeutic. We are proud the development program has been successfully completed, and that, through this agreement, more patients will gain access to highly effective treatments for vision loss including for age-related macular degeneration. This is another demonstration of our passion for providing safe and effective medicines to patients.”
About the Ranibizumab biosimilar
The Ranibizumab biosimilar, FYB201, was originally licensed in from Formycon AG (FRA: FYB/ WKN A1EWVY), a leading German biosimilars company, and subsequently developed by Bioeq AG, a joint venture between Polpharma Biologics and Santo Holding AG (Strüngmann Group). Phase III clinical trials for FYB201 have clinically demonstrated that the efficacy of FYB201 in patients with nAMD is comparable to that of Lucentis®.
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.
-------------------------------------------------------------------------------------------------------------------------------------------
About the Polpharma Biologics Group
Polpharma Biologics Group is a biopharmaceutical group focused on the development and manufacture of biosimilars. It provides fully integrated solutions along the biopharmaceutical value chain including cell line development, product and process development and clinical and commercial scale manufacturing to support the development of its proprietary portfolio of products and those of industry partners around the globe.
Polpharma Biologics has two sites in Poland, an advanced research and development center in Gdansk and a commercial scale manufacturing facility in Warsaw. It also has a research center in the Netherlands.
It is the largest Polish biotechnological firm developing and manufacturing biosimilars. It has been active for over 10 years on a scale previously unknown in the Polish biotechnological sector, investing not only in labs and production lines, but also in know-how, creating highly specialised work places and developing co-operation between business and science.
The Group currently employs over 800 people in Poland, including top-class specialists from the country and from around the world.
Learn more at www.polpharmabiologics.com
About Bioeq
Bioeq AG is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.
Learn more at www.bioeq.ch
About Teva
Teva Pharmaceutical Industries Ltd. has been developing and producing medicines to improve people’s lives for more than a century. Teva is a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with an established presence in generics, they have significant innovative research and operations supporting a growing portfolio of specialty and biopharmaceutical products.
Learn more at www.tevapharm.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005415/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Shift Report Highlights Systemic Vulnerabilities Caused by the Hidden Cost of AI14.1.2026 10:00:00 CET | Press release
Arthur D. Little’s Blue Shift institute has published its latest report, AI’s Hidden Dependencies. This in-depth report, involving more than 50 experts, explores AI’s resource dependencies and the consequent direct systemic vulnerabilities for businesses and lays out strategic actions in response. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114966898/en/ Arthur D. Little’s Blue Shift Institute has published its latest report, AI’s Hidden Dependencies With AI’s adoption and usage expected to remain on its growth trajectory, so is its strain on resources. The report notably identifies three main areas of dependency: Environmental impacts, including emissions due to AI’s heavy energy usage and the manufacture of related hardware Energy supply, including increased electricity demand and strain on the grid Compute infrastructure, including supply chain choke points and dependencies on dominant providers As AI is now becomin
Klarna Expands Digital Bank Offer with Peer-to-Peer Payments14.1.2026 09:00:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, has launched instant peer-to-peer payments in 13 European countries, marking the next step in its evolution as a digital bank. The new feature enables Klarna customers to send money to friends and family, whether splitting bills or gifting cash, directly from the Klarna app: as simple as handing someone cash, with the protection of a regulated bank. This launch takes Klarna deeper into everyday banking, turning Klarna into a central hub for day-to-day spending and money management. It comes on the back of the Klarna Balance accounts and the rapid adoption of Klarna Card, with over 4 million sign-ups just four months after launch. Sebastian Siemiatkowski, co-founder and CEO of Klarna commented: “Customers are sick of the friction and fees of traditional banking, which is why millions signed up to Klarna Card within a few months of launch. With peer-to-peer payments we’re making it even easier to manage all of your payments
Northern Trust Secures Expanded Mandate with Swedish Pension Provider AMF Tjänstepension AB14.1.2026 09:00:00 CET | Press release
Providing Global Custody and Investment Operations Northern Trust (Nasdaq: NTRS) today announced that it has retained and expanded its mandate with AMF Tjänstepension AB (AMF), a leading Swedish pension provider. Under the renewed agreement, Northern Trust, which has serviced AMF for more than 20 years, will continue to serve as custodian for AMF’s global pension assets and add investment operations for trade services across AMF’s total portfolio, for both pension and fund company assets. AMF is one of Sweden’s leading pension companies, managing occupational pensions for millions of individuals. With a strong focus on delivering secure and sustainable retirement outcomes, AMF combines cost efficiency with long-term investment strategies to benefit its members. Petra Sjögerås, head of Nordic Region, Northern Trust said: “As a long-standing partner to institutions in the Nordic region, Northern Trust brings extensive experience and a solutions-oriented mindset to proactively support our
Notice Concerning Change of Representative Executive Officer14.1.2026 08:14:00 CET | Press release
H.U. Group Holdings, Inc. (the Company) today announced that it has resolved, at a meeting of the Board of Directors held on January 14, 2026, to change the Company’s Representative Executive Officer as described below. 1. Name and job titles of newly appointed Representative Executive Officer Name New title Current title Goki Ishikawa Representative Executive Officer, President and Group CEO Managing Executive Officer 2. Name and job titles of retiring Representative Executive Officer Name New title Current title Shigekazu Takeuchi Director and Executive Officer Director, Representative Executive Officer, Chairman, President and Group CEO 3. Reason for change In May 2025, toward realizing its Vision for 2035, the Company announced its Medium-Term Management Plan “H.U. 2030” (MMP) as well as its CEO succession plan including the timing for the selection of the next CEO. As the succession plan progressed, the Company has recognized that Mr. Goki Ishikawa is the best to lead the executio
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics14.1.2026 07:00:00 CET | Press release
Galderma will present data on Relfydess® (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology – which further demonstrate its rapid onset and efficacy through 6 months in both moderate-to-severe frown lines (glabellar lines) and crow’s feet (lateral canthal lines)1-3 Dysport® (AbobotulinumtoxinA) data demonstrating high levels of patient and practitioner satisfaction after treatment of frown lines will also be presented4,5 Galderma will also present a Masterclass on the science behind Relfydess, demonstrating how the company is shaping the future of neuromodulation Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January 14-17, 2026. The company will share data from five abstracts on two neuromodulators from its portfolio, Relfydess – the first and only ready-to-use liquid neuromodulator designed with PEARL Tech
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom